<DOC>
	<DOC>NCT02982148</DOC>
	<brief_summary>This study is designed to compare the effectiveness of intradermal injection and subcutaneous injection with methylene blue for early-stage breast cancer patients who need sentinel lymph node biopsy.</brief_summary>
	<brief_title>Methylene Blue Intradermal Injection for Sentinel Lymph Node Biopsy for Breast Cancer Patients</brief_title>
	<detailed_description>After fully informing and consent, patients recruited would be randomized 1:1 to intradermal injection group and subcutaneous injection group. Investigators aimed to find out the difference in sentinel lymph nodes detected rate, blue lymphatic detected rate and complication incidence between the two groups.</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Methylene Blue</mesh_term>
	<criteria>who sign the informed consent form pathological diagnosed, without distant metastasis, early stage invasive breast cancer patients did not undergo neoadjuvant chemotherapy, endocrinotherapy or targeted therapy previously without breast and axillary surgery history Ejection fraction score in normal range accord to cardiac doppler Eastern Cooperative Oncology Group score â‰¤02 axillary lymph node clinical negative pregnancy any history of malignant tumor within five years diagnosis of multicenter, multifocal or bilateral breast cancer history of breast tumor incision biopsy or vacuumassisted biopsy methylene blue allergic appear with severe systematic disease or disfunction of any organ</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>sentinel lymph node biopsy</keyword>
	<keyword>methylene blue</keyword>
	<keyword>intradermal injection</keyword>
	<keyword>subcutaneous injection</keyword>
</DOC>